erich vogt symposium triumf’s current and future impact in nuclear medicine and molecular imaging...

29
ERICH VOGT SYMPOSIUM TRIUMF’S CURRENT AND FUTURE IMPACT IN NUCLEAR MEDICINE AND MOLECULAR IMAGING OF CANCER Dr. François Bénard BC Leadership Chair in Functional Cancer Imaging

Upload: katrina-appling

Post on 14-Dec-2015

217 views

Category:

Documents


3 download

TRANSCRIPT

Page 1: ERICH VOGT SYMPOSIUM TRIUMF’S CURRENT AND FUTURE IMPACT IN NUCLEAR MEDICINE AND MOLECULAR IMAGING OF CANCER Dr. François Bénard BC Leadership Chair in

ERICH VOGT SYMPOSIUM

TRIUMF’S CURRENT AND FUTURE IMPACT IN NUCLEAR MEDICINE AND MOLECULAR IMAGING OF CANCER

Dr. François Bénard

BC Leadership Chair in Functional Cancer Imaging

Page 2: ERICH VOGT SYMPOSIUM TRIUMF’S CURRENT AND FUTURE IMPACT IN NUCLEAR MEDICINE AND MOLECULAR IMAGING OF CANCER Dr. François Bénard BC Leadership Chair in

A Brief History of Nuclear Medicine• 1930s: Discovery of artificial isotopes, notably Iodine-131 and

Tc99m• First treatment in 1939 with phosphorus-32• First treatment with iodine-131 in 1946• Gamma camera (Anger) and Rectilinear Scanner (Cassen) in

1950s• Thyroid imaging 1950-1960• Liver/spleen scanning, bone imaging, brain tumour

localization 1960-1970s• Positron emission tomography in 1970s+ for brain imaging• Cardiac imaging 1980s+• Cancer imaging in the 1990s and beyond

Page 3: ERICH VOGT SYMPOSIUM TRIUMF’S CURRENT AND FUTURE IMPACT IN NUCLEAR MEDICINE AND MOLECULAR IMAGING OF CANCER Dr. François Bénard BC Leadership Chair in

Some Definitions• SPECT: Single photon emission computed tomography

• Three dimensional images acquired from the single photon emission produced by gamma emission decay

• Typical isotopes: Tc-99m, In-111, Tl-201, I-123,…

• PET: Positron emission tomography• Three dimensional images acquired from the dual photon emission

produced by the annihilation of a positron• Typical isotopes: C-11, F-18, Ga-68, O-15, Rb-82, …

Page 4: ERICH VOGT SYMPOSIUM TRIUMF’S CURRENT AND FUTURE IMPACT IN NUCLEAR MEDICINE AND MOLECULAR IMAGING OF CANCER Dr. François Bénard BC Leadership Chair in

Technetium-99m, the Medical Isotope of the 20th Century

• Element 43 discovered by Carlo Perrier and Emilio Segrè in 1936

• Technetium-99 discovered by Seaborg and Segrè at the Berkeley Radiation Laboratory

• BNL, 1950s: Tucker and Green developed the first 99Mo/99mTc generator

• BNL, 1960: Powell Richards, presented the first paper on the generator.

• Richards met with Paul Harper on the flight to Rome and spent the flight “extolling the merits of 99mTc”

In part from http://www.bnl.gov/bnlweb/history/Tc-99m.asp

Tucker and Richards

Page 5: ERICH VOGT SYMPOSIUM TRIUMF’S CURRENT AND FUTURE IMPACT IN NUCLEAR MEDICINE AND MOLECULAR IMAGING OF CANCER Dr. François Bénard BC Leadership Chair in

Single Photon Emitters in Oncology

99mTc MDP Bone Scan

99mTc Sulfur Colloid Sentinel Node Detection

111In Pentetreotide for neuroendocrine cancers

99mTc Sestamibi Breast Cancer Detection

Page 6: ERICH VOGT SYMPOSIUM TRIUMF’S CURRENT AND FUTURE IMPACT IN NUCLEAR MEDICINE AND MOLECULAR IMAGING OF CANCER Dr. François Bénard BC Leadership Chair in

Accelerator Produced Single Photon Emitters

• Iodine-123• Thyroid imaging• Thyroid cancer detection

• Gallium-67• Infection/inflammation imaging

• Indium-111• Infection imaging, tumour imaging with peptides and antibodies

• Thallium-201• Cardiac imaging

All made at TRIUMF…

Page 7: ERICH VOGT SYMPOSIUM TRIUMF’S CURRENT AND FUTURE IMPACT IN NUCLEAR MEDICINE AND MOLECULAR IMAGING OF CANCER Dr. François Bénard BC Leadership Chair in
Page 8: ERICH VOGT SYMPOSIUM TRIUMF’S CURRENT AND FUTURE IMPACT IN NUCLEAR MEDICINE AND MOLECULAR IMAGING OF CANCER Dr. François Bénard BC Leadership Chair in

99mTc Production by Cyclotrons

• Concept proven by several authors in past 40 years at low proton beam currents• Beaver and Hupf, J Nucl Med 1971; 12:739-741• Lagunas-Solar et al., Appl Radiat Isot 1991; 42:543• Levkovskii N et al. 1991• Scholten et al., Appl Rad Isot 1999; 6-80

J Nucl Med 1971; 12: 739-741

Page 9: ERICH VOGT SYMPOSIUM TRIUMF’S CURRENT AND FUTURE IMPACT IN NUCLEAR MEDICINE AND MOLECULAR IMAGING OF CANCER Dr. François Bénard BC Leadership Chair in

The Technology

Page 10: ERICH VOGT SYMPOSIUM TRIUMF’S CURRENT AND FUTURE IMPACT IN NUCLEAR MEDICINE AND MOLECULAR IMAGING OF CANCER Dr. François Bénard BC Leadership Chair in

Can Cyclotrons help prevent isotope shortages?

• Distribution model established for 18F-Fluorodeoxyglucose (110 min half-life)

• Mixed model possible for 18F (1 h irradiation) and 99mTc production (3-6 h irradiations)

• Take advantage of existing infrastructure

Page 11: ERICH VOGT SYMPOSIUM TRIUMF’S CURRENT AND FUTURE IMPACT IN NUCLEAR MEDICINE AND MOLECULAR IMAGING OF CANCER Dr. François Bénard BC Leadership Chair in

Vision• Paradigm well suited to central radiopharmacies• Cyclotron capability can be tailored to market• Multiple cyclotrons provide redundancy• Synergy between PET & SPECT

• Utilize existing PET cyclotrons to diversify Tc99m supply• More cyclotrons will facilitate the transition of nuclear

medicine imaging infrastructure, from SPECT to PET

• Complementary to LINAC/other sources of 99Mo• Generators freed up for remote areas

Page 12: ERICH VOGT SYMPOSIUM TRIUMF’S CURRENT AND FUTURE IMPACT IN NUCLEAR MEDICINE AND MOLECULAR IMAGING OF CANCER Dr. François Bénard BC Leadership Chair in

•Daily irradiation of Tc99m•Regional/Supraregional distribution

• 6-hour half-life• Can be combined with 18F-FDG distribution

• Shipping by road or air

•Processing and release currently takes ~2 h

The Technology

Page 13: ERICH VOGT SYMPOSIUM TRIUMF’S CURRENT AND FUTURE IMPACT IN NUCLEAR MEDICINE AND MOLECULAR IMAGING OF CANCER Dr. François Bénard BC Leadership Chair in

Canadian Cyclotron Infrastructure• 24 Cyclotrons in Canada

• 6 in Vancouver• 4 in Toronto• 3 in Montreal• 2 each in Hamilton, Edmonton, Sherbrooke• 1 in Winnipeg, London (ON), Ottawa, Halifax,

Saskatoon

• 3 new cyclotrons planned or purchased• Thunder Bay, St-John’s, Vancouver

Worldwide: 889 cyclotrons in 2013

Page 14: ERICH VOGT SYMPOSIUM TRIUMF’S CURRENT AND FUTURE IMPACT IN NUCLEAR MEDICINE AND MOLECULAR IMAGING OF CANCER Dr. François Bénard BC Leadership Chair in

Determinants of Tc-99m yield• Proton beam current

• Expressed in µA (microampers)

• Proton beam energy• Expressed in MeV (megaelectron-volts)• Production starts around 8-10 MeV, peaks at 15 MeV• Higher energy means thicker proton penetration = higher yield

• Examples of theoretical yields (6 h runs)• 130 µA, 16.5 MeV (GE cyclotron): 4.9 Ci• 160 µA, 16.5 MeV (GE cyclotron): 6.1 Ci• 300 µA, 18 MeV (TR19 cyclotron): 15.4 Ci• 300 µA, 20 MeV (TR24 cyclotron): 18.7 Ci• 500 µA, 20 MeV (TR24 cyclotron): 31.1 Ci• 500 µA, 24 MeV (TR24 cyclotron): 39.2 Ci

• Practical net yields 85-95% of theoretical

June 3, 2014Achieving Large Scale Production, Distribution, and

Commercialization of Tc-99m 14

Page 15: ERICH VOGT SYMPOSIUM TRIUMF’S CURRENT AND FUTURE IMPACT IN NUCLEAR MEDICINE AND MOLECULAR IMAGING OF CANCER Dr. François Bénard BC Leadership Chair in
Page 16: ERICH VOGT SYMPOSIUM TRIUMF’S CURRENT AND FUTURE IMPACT IN NUCLEAR MEDICINE AND MOLECULAR IMAGING OF CANCER Dr. François Bénard BC Leadership Chair in
Page 17: ERICH VOGT SYMPOSIUM TRIUMF’S CURRENT AND FUTURE IMPACT IN NUCLEAR MEDICINE AND MOLECULAR IMAGING OF CANCER Dr. François Bénard BC Leadership Chair in
Page 18: ERICH VOGT SYMPOSIUM TRIUMF’S CURRENT AND FUTURE IMPACT IN NUCLEAR MEDICINE AND MOLECULAR IMAGING OF CANCER Dr. François Bénard BC Leadership Chair in
Page 19: ERICH VOGT SYMPOSIUM TRIUMF’S CURRENT AND FUTURE IMPACT IN NUCLEAR MEDICINE AND MOLECULAR IMAGING OF CANCER Dr. François Bénard BC Leadership Chair in
Page 20: ERICH VOGT SYMPOSIUM TRIUMF’S CURRENT AND FUTURE IMPACT IN NUCLEAR MEDICINE AND MOLECULAR IMAGING OF CANCER Dr. François Bénard BC Leadership Chair in

Preclinical images – 99mTc-MDP (bone scan)Mouse injected 24 h after production

Page 21: ERICH VOGT SYMPOSIUM TRIUMF’S CURRENT AND FUTURE IMPACT IN NUCLEAR MEDICINE AND MOLECULAR IMAGING OF CANCER Dr. François Bénard BC Leadership Chair in

Will Other Modalities Replace 99mTc?

The Supply of Medical Radioisotopes, Nuclear Energy Agency, OECD, 2011

Page 22: ERICH VOGT SYMPOSIUM TRIUMF’S CURRENT AND FUTURE IMPACT IN NUCLEAR MEDICINE AND MOLECULAR IMAGING OF CANCER Dr. François Bénard BC Leadership Chair in

How TRIUMF helped other PET programs in Canada

• Started the UBC PET program for neuroimaging• Sent radioisotopes to Edmonton to help them start their

PET program on cancer imaging• Allowed BCCA to setup 18F-FDG production at TRIUMF to

ship isotopes for cancer imaging• Helped the Ottawa Heart Institute setup their 82Sr/82Rb

generator which started their cardiac PET program• Set up 64Cu production at Sherbrooke

Page 23: ERICH VOGT SYMPOSIUM TRIUMF’S CURRENT AND FUTURE IMPACT IN NUCLEAR MEDICINE AND MOLECULAR IMAGING OF CANCER Dr. François Bénard BC Leadership Chair in

Replacement of 99mTc with PET studies

• 17% of nuclear medicine studies are bone scans• Can be replaced with 18F-NaF

• 56% myocardial perfusion studies• Can be replaced with 82Rb, 18F-Flurpiridaz, 18F-

phosphonium cations

Page 24: ERICH VOGT SYMPOSIUM TRIUMF’S CURRENT AND FUTURE IMPACT IN NUCLEAR MEDICINE AND MOLECULAR IMAGING OF CANCER Dr. François Bénard BC Leadership Chair in

99mTc Bone Scan 18F PET Scan

Page 25: ERICH VOGT SYMPOSIUM TRIUMF’S CURRENT AND FUTURE IMPACT IN NUCLEAR MEDICINE AND MOLECULAR IMAGING OF CANCER Dr. François Bénard BC Leadership Chair in

Myocardial Imaging with PET

Maddahi J., J Nucl Cardiol 2012; 19, Suppl 1, S30-7

13N-NH3 and 18F-FDG for viability

82RbCl – Courtesy, University of Ottawa

Page 26: ERICH VOGT SYMPOSIUM TRIUMF’S CURRENT AND FUTURE IMPACT IN NUCLEAR MEDICINE AND MOLECULAR IMAGING OF CANCER Dr. François Bénard BC Leadership Chair in

Cancer Imaging Targets BCCA/TRIUMF

Page 27: ERICH VOGT SYMPOSIUM TRIUMF’S CURRENT AND FUTURE IMPACT IN NUCLEAR MEDICINE AND MOLECULAR IMAGING OF CANCER Dr. François Bénard BC Leadership Chair in

Future radiotracers for cancer imaging

24 hr 48 hr 72 hr 5 days 7 days

sl

th

68Ga-bradykinin imaging Radiolabeled antibodies

68Ga CA-IX imaging18F-bombesin imaging

Page 28: ERICH VOGT SYMPOSIUM TRIUMF’S CURRENT AND FUTURE IMPACT IN NUCLEAR MEDICINE AND MOLECULAR IMAGING OF CANCER Dr. François Bénard BC Leadership Chair in

Erich Vogt - Bridging the gap between Physics and Medicine

Pilfered from http://vogt.physics.ubc.ca/vogt/gallery/

Page 29: ERICH VOGT SYMPOSIUM TRIUMF’S CURRENT AND FUTURE IMPACT IN NUCLEAR MEDICINE AND MOLECULAR IMAGING OF CANCER Dr. François Bénard BC Leadership Chair in

TRIUMF’s Contributions for the Future

• Continue developments in radiochemistry and imaging probes

• Secure radioisotope supply for British Columbia for all nuclear medicine radioisotopes

• Development of alpha emitter radionuclide therapy• Development of exotic medical radioisotopes• Expansion of proton therapy?